跳至主要内容
临床试验/NCT05538806
NCT05538806招募中不适用

TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study - TIGER Meso Study

NovoCure GmbH23 个研究点 分布在 3 个国家目标入组 198 人开始时间: 2023年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
NovoCure GmbH
入组人数
198
试验地点
23
主要终点
Time from diagnosis of pleural mesothelioma to death of any cause as median overall survival time.

研究概览

简要总结

The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥ 18 years of age
  • Histologically confirmed pleural mesothelioma without any option of curative resection
  • Planned treatment with NovoTTF-200T System according to IFU and medical guidelines
  • Life expectancy more than 3 months at day of enrollment
  • Signed informed consent for use and processing of data

排除标准

  • Previous treatment with NovoTTF-200T for more than 1 week at day of enrollment

结局指标

主要结局

Time from diagnosis of pleural mesothelioma to death of any cause as median overall survival time.

时间窗: 54 Months

次要结局

  • Changes in quality of life comparing baseline with 3 and 6 months after start of TTFields therapy.(QoL will be assessed at baseline, 3 and 6 months.)
  • Number of TTFields treatment-related SAEs, as assessed by the CEC, within total observation period, standardized to average annual incidences.(3 years + 18 months follow up)

研究者

发起方
NovoCure GmbH
申办方类型
Industry
责任方
Sponsor

研究点 (23)

Loading locations...

相似试验